TNF Pharmaceutical Shares Positive Data Expanding Clinical Trial For Sarcopenia

TNF Pharmaceuticals, Inc. is a biopharmaceutical company that develops new oral treatments for autoimmune and inflammatory diseases. The firm has announced that its experimental drug, isomyosamine, has achieved a new milestone. The company completed a 13-week FDA-recommended safety study, showing that isomyosamine is safe at all tested doses, allowing expanded and longer clinical trials in multiple conditions.

Mitchell Glass, M.D., President and Chief Medical Officer of TNFA, said, “Positive data from this milestone study confirms isomyosamine’s historically strong safety profile and enables us to extend the duration of future clinical trials. We believe we are fully equipped to advance our comprehensive isomyosamine platform in a longer-term clinical trial in sarcopenia and future studies in multiple conditions associated with immunometabolic dysregulation.”

TNF Pharmaceuticals plans to start a Phase 2b trial early in 2025 to evaluate isomyosamine’s ability to treat sarcopenia (muscle loss associated with ageing) and frailty. This follows positive results from an earlier study. The sarcopenia treatment market is expected to grow from $3.07 billion in 2024 to $4.02 billion by 2029.

The company is also preparing a study to test isomyosamine in people experiencing muscle loss and inflammation linked to GLP-1 medications like Wegovy and Ozempic. These drugs are used for weight loss, and diabetes is a rapidly growing market estimated to reach $105 billion by 2029. This trial will examine whether isomyosamine can address inflammation and muscle loss, providing new hope for patients managing obesity or diabetes.

Isomyosamine belongs to the TNF inhibitor drug class, which is already a $39.7 billion global market in 2024 and is expected to grow to $47.3 billion by 2029. TNF Pharmaceuticals aims to provide a novel, oral option in this well-established treatment category.